Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus  

作　　者：Hiroyuki Konya Masayuki Miuchi Kahori Satani Satoshi Matsutani Yuzo Yano Taku Tsunoda Takashi Ikawa Toshihiro Matsuo Fumihiro Ochi Yoshiki Kusunoki Masaru Tokuda Tomoyuki Katsuno Tomoya Hamaguchi Jun-ichiro Miyagawa Mitsuyoshi Namba 

机构地区：[1]Department of Internal Medicine, Ashiya Municipal Hospital [2]Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, Hyogo College of Medicine [3]Division of Innovative Diabetes Treatment, Department of Internal Medicine, Hyogo College of Medicine [4]Center of Diabetes Therapy, Department of Internal Medicine, Itami City Hospital

出　　处：《World Journal of Experimental Medicine》2015年第2期110-119,共10页世界实验医学杂志

摘　　要：Cardiovascular(CV) complications are an essential causal element of prospect in diabetes mellitus(DM), with carotid atherosclerosis being a common risk factor for prospective crisis of coronary artery diseases and/or cerebral infarction in DM subjects. From another point of view, asymmetric dimethylarginine(ADMA) has been established as an inhibitor of endogenous nitric oxide synthesis and the relationship between ADMA and arteriosclerosis has been reported. In our study with 87 type 2 DM(T2DM) patients, we have examined whether ADMA and other CV risk factors are the useful predictors of DMCV complications. After the measurement of the respective CV risk factors, we have followed the enrolled T2 DM patients for 5 years. We have finally analyzed 77 patients. DMCV complications developed in 15 cases newly within 5 years, and 4 cases recurred. The concentrations of ADMA in plasma were markedly more elevated in 19 DM patients with CV complications than in 58 DM patients without CV complications. Urinary albumin(U-Alb), mean intimal-medial thickness(IMT) and ankle brachial index(ABI) were also higher in patients with CV complications. Multiple regression analyses showed that U-Alb had an influence on the high level of ADMA(standardized β = 6.59, P = 0.00014) independently of age, systolic BP, fibrinogen, mean IMT, plaque score, and ABI. The review indicates what is presently known regarding plasma ADMA that might be a new and meaningful biomarker of CV complications in DM subjects.Cardiovascular(CV) complications are an essential causal element of prospect in diabetes mellitus(DM), with carotid atherosclerosis being a common risk factor for prospective crisis of coronary artery diseases and/or cerebral infarction in DM subjects. From another point of view, asymmetric dimethylarginine(ADMA) has been established as an inhibitor of endogenous nitric oxide synthesis and the relationship between ADMA and arteriosclerosis has been reported. In our study with 87 type 2 DM(T2DM) patients, we have examined whether ADMA and other CV risk factors are the useful predictors of DMCV complications. After the measurement of the respective CV risk factors, we have followed the enrolled T2 DM patients for 5 years. We have finally analyzed 77 patients. DMCV complications developed in 15 cases newly within 5 years, and 4 cases recurred. The concentrations of ADMA in plasma were markedly more elevated in 19 DM patients with CV complications than in 58 DM patients without CV complications. Urinary albumin(U-Alb), mean intimal-medial thickness(IMT) and ankle brachial index(ABI) were also higher in patients with CV complications. Multiple regression analyses showed that U-Alb had an influence on the high level of ADMA(standardized β = 6.59, P = 0.00014) independently of age, systolic BP, fibrinogen, mean IMT, plaque score, and ABI. The review indicates what is presently known regarding plasma ADMA that might be a new and meaningful biomarker of CV complications in DM subjects.

关 键 词：Asymmetric DIMETHYLARGININE BIOMARKER Diabetes MELLITUS CARDIOVASCULAR complications INCRETIN 

分 类 号：R[医药卫生]